We recently published a list of These 10 Firms Were Thursday’s Top Performers. In this article, we are going to take a look ...

We recently compiled a list of the These 10 Companies Led Gains on Wednesday. In this article, we are going to take a look at ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (NASDAQ: MRNA). The company, which was a leader in developing one of the ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but the gains didn't last long. Since reaching a peak last May, Moderna ...

Ratings for Moderna (NASDAQ:MRNA) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ...

Moderna MRNA announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”), has awarded the company $590 million to accelerate the ...